Open AccessPB1883: TIME‐LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT‐NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL.
Author(s) -
Burger J.,
Sivina M.,
Kim E.,
Issa G.,
Wierda W.,
Jain N.,
Thompson P.,
Ferrajoli A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850384.35364.fa
Subject(s) - medicine , discontinuation , obinutuzumab , regimen , chronic lymphocytic leukemia , gastroenterology , oncology , leukemia